Celastrol ameliorates acute liver injury through modulation of PPARα

Qi Zhao,Ping Tang,Ting Zhang,Jian-Feng Huang,Xue-Rong Xiao,Wei-Feng Zhu,Fei Li,Frank J. Gonzalez
DOI: https://doi.org/10.1016/j.bcp.2020.114058
IF: 6.1
2020-08-01
Biochemical Pharmacology
Abstract:<p>Celastrol, derived from the roots of the <em>Tripterygium Wilfordi</em>, has attracted interest for its potential anti-inflammatory and lipid-lowering activities. In the present study, the protective effect of celastrol on carbon tetrachloride (CCl<sub>4</sub>)-induced acute liver injury was investigated. Celastrol improved the increased transaminase activity, inflammation, and oxidative stress induced by CCl<sub>4</sub>, resulting in improved metabolic disorders found in mice with liver injury. Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor α (PPARα) signaling mediated the protective effect of celastrol, which was not observed in <em>Ppara</em>-null mice, and co-treatment of wild-type mice with the PPARα antagonist GW6471. Mechanistically, PPARα deficiency potentiated CCl<sub>4</sub>-induced liver injury through a deoxycholic acid (DCA)-EGR1-inflammatory factor axis. These data demonstrate a novel role for celastrol in protection against acute liver injury through modulating PPARα signaling.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?